Carlo Zanon
Research Subjects
Carlo Zanon has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
- Alberto Bardelli
IFOM ETS - The AIRC Institute of Molecular Oncology, Milan, Italy
13 shared publications - Federica Di Nicolantonio
Department of Oncology, University of Torino, Torino, Italy
13 shared publications - Alessio Amatu
Department of Hematology, Oncology, and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy
12 shared publications - Andrea Bertotti
Candiolo Cancer Institute—FPO IRCCS, Torino, Italy
12 shared publications - Andrea Cassingena
Niguarda Cancer Center, Milan, Italy
12 shared publications - Andrea Sartore-Bianchi
Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy
12 shared publications
Latest Publications
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
Supplementary Figure S5 - PDF file 777K, Schematic representation of the scoring system applied to assess MET protein expression by immunohistochemistry
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
Supplementary Figure S5 - PDF file 777K, Schematic representation of the scoring system applied to assess MET protein expression by immunohistochemistry
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
Supplementary Figure S4 - PDF file 19K, Ectopic expression of MET in cetuximab sensitive DIFI and LIM1215 cell lines
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
Supplementary Figure S4 - PDF file 19K, Ectopic expression of MET in cetuximab sensitive DIFI and LIM1215 cell lines